Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
Website: treace.com



Growth: Good revenue growth rate 24.0%, there is slowdown compared to average historical growth rates 40.8%. The revenue growth dynamics is stable

Profitability: LTM EBITDA margin is negative, -24.6%. On average the margin is decreasing steadily. Gross margin is high, +81.6%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 6.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 82.4% higher than minimum and 69.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.1x by EV / Sales multiple , the company can be 28.0% overvalued

Key Financials (Download financials)

Ticker: TMCI
Share price, USD:  (+2.7%)11
year average price 15.53  


year start price 26.47 2023-05-07

max close price 26.90 2023-05-22

min close price 6.03 2023-11-13

current price 11.00 2024-05-05
Common stocks: 55 558 364

Dividend Yield:  0.0%
Last revenue growth (y/y):  24.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  40.8%
Historical growth of EBITDA:  ---
EV / Sales: 3.0x
Margin (EBITDA LTM / Revenue): -24.6%
Fundamental value created in LTM:
Market Cap ($m): 611
Net Debt ($m): -54
EV (Enterprise Value): 557
Price to Book: 4.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-09GlobeNewsWire

Treace to Report First Quarter 2024 Financial Results

2024-02-28Seeking Alpha

Treace Medical Concepts Inc (TMCI) Q4 2023 Earnings Call Transcript

2024-02-27Zacks Investment Research

Treace Medical Concepts (TMCI) Reports Q4 Loss, Tops Revenue Estimates

2023-11-11Seeking Alpha

Treace Medical Concepts, Inc. (TMCI) Q3 2023 Earnings Call Transcript

2023-10-27Seeking Alpha

Treace Medical Concepts Continues Growth Investments Despite High Operating Losses

2023-08-22GlobeNewsWire

Treace Announces Participation in the 21st Annual Morgan Stanley Global Healthcare Conference

2023-07-20Seeking Alpha

Treace Medical: New Surgeons, Higher ASPs, And More Lapiplasties: A Positive Trend

2023-05-08Seeking Alpha

Treace Medical Concepts, Inc. (TMCI) Q1 2023 Earnings Call Transcript

2023-04-20GlobeNewsWire

Treace to Report First Quarter 2023 Financial Results on May 8, 2023

2023-04-10Zacks Investment Research

Treace Medical Concepts (TMCI) Surges 7.6%: Is This an Indication of Further Gains?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TMCI TMCI TMCI TMCI TMCI TMCI
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-09 2023-08-09 2023-05-09 2023-03-08 2022-11-09
acceptedDate 2024-02-27 16:29:40 2023-11-09 16:14:24 2023-08-09 08:09:39 2023-05-09 08:01:14 2023-03-08 09:09:06 2022-11-09 08:34:07
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 62M 41M 42M 42M 50M 33M
costOfRevenue 11M 8M 8M 8M 10M 7M
grossProfit 51M 33M 34M 34M 40M 26M
grossProfitRatio 0.816 0.804 0.817 0.809 0.804 0.800
researchAndDevelopmentExpenses 4M 4M 4M 3M 4M 4M
generalAndAdministrativeExpenses 13M 13M 10M 11M 10M 9M
sellingAndMarketingExpenses 40M 34M 34M 34M 29M 25M
sellingGeneralAndAdministrativeExpenses 53M 46M 44M 45M 40M 34M
otherExpenses 96 000 23 000 95 000 128 000 0 0
operatingExpenses 58M 51M 47M 48M 44M 38M
costAndExpenses 69M 59M 55M 56M 53M 44M
interestIncome 2M 2M 2M 1M 396 000 375 000
interestExpense 1M -1M 1M 1M 1M 1M
depreciationAndAmortization 2M 2M 1M 3M 396 000 834 000
ebitda -5M -18M -10M -11M -3M -10M
ebitdaratio -0.081 -0.437 -0.236 -0.267 -0.062 -0.317
operatingIncome -7M -18M -13M -14M -3M -11M
operatingIncomeRatio -0.109 -0.437 -0.311 -0.326 -0.070 -0.342
totalOtherIncomeExpensesNet 501 000 297 000 95 000 322 000 -915 000 -815 000
incomeBeforeTax -6M -18M -12M -13M -4M -12M
incomeBeforeTaxRatio -0.101 -0.430 -0.292 -0.319 -0.089 -0.367
incomeTaxExpense 0 -2M 1M -322 000 -917 000 815 000
netIncome -6M -18M -12M -13M -3M -13M
netIncomeRatio -0.101 -0.430 -0.292 -0.311 -0.070 -0.392
eps -0.100 -0.280 -0.200 -0.220 -0.063 -0.230
epsdiluted -0.100 -0.280 -0.200 -0.220 -0.063 -0.230
weightedAverageShsOut 62M 62M 61M 59M 56M 55M
weightedAverageShsOutDil 62M 62M 61M 59M 56M 55M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TMCI TMCI TMCI TMCI TMCI TMCI
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-09 2023-08-09 2023-05-09 2023-03-08 2022-11-09
acceptedDate 2024-02-27 16:29:40 2023-11-09 16:14:24 2023-08-09 08:09:39 2023-05-09 08:01:14 2023-03-08 09:09:06 2022-11-09 08:34:07
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 13M 7M 12M 30M 19M 89M
shortTermInvestments 110M 115M 127M 141M 62M 0
cashAndShortTermInvestments 123M 122M 139M 171M 81M 89M
netReceivables 38M 25M 27M 25M 29M 19M
inventory 29M 29M 26M 23M 19M 17M
otherCurrentAssets 8M 11M 5M 5M 4M 4M
totalCurrentAssets 198M 187M 198M 223M 133M 128M
propertyPlantEquipmentNet 32M 31M 29M 26M 25M 28M
goodwill 13M 13M 13M 0 0 0
intangibleAssets 9M 9M 10M 0 0 0
goodwillAndIntangibleAssets 22M 22M 22M 0 0 0
longTermInvestments 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 146 000 146 000 146 000 215 000 146 000 146 000
totalNonCurrentAssets 54M 53M 52M 26M 26M 29M
otherAssets 0 0 0 0 0 0
totalAssets 252M 240M 250M 249M 159M 156M
accountPayables 12M 9M 8M 5M 9M 8M
shortTermDebt 1M 1M 4M 1M 339 000 330 000
taxPayables 0 0 0 0 0 0
deferredRevenue 0 20M -4M 0 0 0
otherCurrentLiabilities 32M 3M 22M 17M 21M 14M
totalCurrentLiabilities 45M 33M 30M 23M 30M 23M
longTermDebt 53M 69M 70M 68M 68M 72M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 16M 37 000 37 000 25 000 0 63M
totalNonCurrentLiabilities 69M 69M 70M 68M 68M 72M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 16M 18M 17M 17M 16M 19M
totalLiabilities 114M 103M 100M 92M 98M 94M
preferredStock 0 0 0 0 0 0
commonStock 62 000 62 000 62 000 61 000 55 000 46 000
retainedEarnings -134M -128M -110M -98M -85M -80M
accumulatedOtherComprehensiveIncomeLoss 163 000 -148 000 -219 000 -56 000 -27 000 0
othertotalStockholdersEquity 272M 266M 261M 256M 145M 142M
totalStockholdersEquity 138M 138M 150M 158M 61M 62M
totalEquity 138M 138M 150M 158M 61M 62M
totalLiabilitiesAndStockholdersEquity 252M 240M 250M 249M 159M 156M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 252M 240M 250M 249M 159M 156M
totalInvestments 110M 115M 127M 141M 62M 0
totalDebt 70M 70M 70M 69M 69M 72M
netDebt 57M 63M 58M 40M 49M -17M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol TMCI TMCI TMCI TMCI TMCI TMCI
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2024-02-27 2023-11-09 2023-08-09 2023-05-09 2023-03-08 2022-11-09
acceptedDate 2024-02-27 16:29:40 2023-11-09 16:14:24 2023-08-09 08:09:39 2023-05-09 08:01:14 2023-03-08 09:09:06 2022-11-09 08:34:07
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -6M -18M -12M -13M -4M -12M
depreciationAndAmortization 2M 2M 1M 924 000 917 000 459 000
deferredIncomeTax -20M -367 000 -326 000 0 0 0
stockBasedCompensation 6M 5M 4M 3M 2M 2M
changeInWorkingCapital -2M 781 000 -1M -8M -6M 980 000
accountsReceivables -13M 2M -2M 4M -11M -2M
inventory 67 000 -3M -4M -3M -3M -4M
accountsPayables 3M 534 000 3M -4M 787 000 5M
otherWorkingCapital 9M 1M 1M -5M 7M 2M
otherNonCashItems 20M 838 000 740 000 443 000 1M 942 000
netCashProvidedByOperatingActivities 532 000 -10M -8M -17M -5M -7M
investmentsInPropertyPlantAndEquipment -2M -4M -4M -1M -2M -6M
acquisitionsNet -7M -8M -20M 710 000 0 0
purchasesOfInvestments -30M -19M -21M -100M -63M 0
salesMaturitiesOfInvestments 37M 27M 35M 21M 2M 0
otherInvestingActivites 7M 8M 0 -710 000 0 0
netCashUsedForInvestingActivites 5M 5M -10M -80M -64M -6M
debtRepayment 0 0 0 0 -34M 0
commonStockIssued 178 000 159 000 1M 108M 2M 0
commonStockRepurchased -13 000 0 -6M 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -13 000 159 000 6M 352 000 32M 353 000
netCashUsedProvidedByFinancingActivities 165 000 159 000 1M 108M 297 000 353 000
effectOfForexChangesOnCash -4M -6M 10M 0 0 0
netChangeInCash 6M -5M -18M 10M -69M -13M
cashAtEndOfPeriod 13M 7M 12M 30M 19M 89M
cashAtBeginningOfPeriod 7M 12M 30M 19M 89M 102M
operatingCashFlow 532 000 -10M -8M -17M -5M -7M
capitalExpenditure -2M -4M -4M -1M -2M -6M
freeCashFlow -2M -13M -13M -19M -8M -13M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-11 ET (fiscal 2023 q3)
2023 q2
2023-08-12 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-03-07 ET (fiscal 2022 q4)
2022 q3
2022-11-12 ET (fiscal 2022 q3)
2022 q2
2022-08-13 ET (fiscal 2022 q2)
2022 q1
2022-05-08 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-27 21:05 ET
Treace Medical Concepts Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Guidance
2024-02-07 21:05 ET
Treace to Report Fourth Quarter and Full-Year 2023 Financial Results
2024-02-02 17:00 ET
Treace Announces Interim 3-Year ALIGN3D™ Clinical Study Data at the 2024 ACFAS Scientific Conference Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
2024-02-01 12:00 ET
Treace to Highlight Latest Product Innovations and ALIGN3D™ Study Outcomes at the 2024 ACFAS Annual Scientific Conference
2024-01-08 12:00 ET
Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue
2023-12-19 12:00 ET
Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-11-09 21:05 ET
Treace Medical Concepts Reports Third Quarter 2023 Financial Results
2023-10-30 11:00 ET
Treace to Present at Stifel 2023 Healthcare Conference
2023-10-16 11:00 ET
Treace to Report Third Quarter 2023 Financial Results
2023-09-20 11:00 ET
Treace Highlights New Product Innovations and Updated ALIGN3D™ Clinical Study Data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2023
2023-09-14 20:05 ET
Treace Medical Concepts Announces New Patent Covering Instrumented Bunion Correction Procedures and Milestone 50th U.S. Patent
2023-09-11 20:05 ET
Treace Medical Concepts Announces Limited Market Release of New Complementary Technologies for Treating Bunions and Related Procedures
2023-08-22 20:05 ET
Treace Announces Participation in the 21st Annual Morgan Stanley Global Healthcare Conference
2023-08-21 11:00 ET
Treace Medical Concepts Appoints Nathan Minnich as Senior Vice President, Marketing
2023-08-08 20:05 ET
Treace Medical Concepts Reports Second Quarter 2023 Financial Results
2023-07-24 20:05 ET
Treace Announces Participation in the UBS Medtech, Tools and Genomics Summit 2023
2023-07-18 20:15 ET
Treace to Report Second Quarter 2023 Financial Results on August 8, 2023
2023-07-12 20:15 ET
Treace Appoints Julie Dewey as Chief Communications and Investor Relations Officer
2023-06-13 20:15 ET
Treace Medical Completes Acquisition of Technology Enabling Patient Specific Instrumentation and Reports on Clinical Cases Using PSI with the Lapiplasty® System
2023-06-01 20:15 ET
Treace Medical Concepts to Acquire Technology Enabling Patient Specific Instrumentation for Foot and Ankle Surgeries
2023-05-08 20:05 ET
Treace Medical Concepts Reports First Quarter 2023 Financial Results
2023-04-26 20:15 ET
Treace Announces Participation in the Bank of America 2023 Healthcare Conference
2023-04-20 20:15 ET
Treace to Report First Quarter 2023 Financial Results on May 8, 2023
2023-04-19 20:15 ET
Treace Medical Expands Market Leading Global IP Portfolio For Bunion And Related Deformities
2023-04-04 20:15 ET
Treace Publishes Inaugural ESG Report
2023-03-07 21:05 ET
Treace Medical Concepts Reports Fourth Quarter and Full Year 2022 Financial Results
2023-03-03 14:03 ET
Treace Medical Announces Settlement of Lawsuit Again Fusion Orthopedics
2023-03-03 03:20 ET
Dispute Between Treace Medical and Fusion Orthopedics Resolved
2023-02-27 21:15 ET
Treace to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
2023-02-09 18:00 ET
Treace Presents Updated ALIGN3D™ Interim Data and Latest Product Innovations at the 2023 ACFAS Annual Conference
2023-02-08 02:15 ET
Treace Medical Concepts, Inc. Announces Pricing of $100.0 Million Public Offering of Common Stock
2023-02-07 21:30 ET
Treace Medical Concepts, Inc. Announces Proposed Public Offering of Common Stock
2023-01-09 13:00 ET
Treace Medical Concepts Provides 2022 Preliminary Unaudited Revenue
2022-12-20 21:15 ET
Treace to Present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023
2022-12-19 21:15 ET
Treace Medical Announces Expansion of Its Global IP Portfolio with the Grant of Two New U.S. Patents
2022-11-28 21:15 ET
Treace Receives FDA 510(k) Clearance for SpeedPlate™ Rapid Compression Implant Technology
2022-11-21 21:15 ET
Treace Announces First Patient Treated in MTA3D™ Adductoplasty® Clinical Study
2022-11-08 21:05 ET
Treace Medical Concepts Reports Third Quarter 2022 Financial Results
2022-10-25 20:15 ET
Treace Announces Participation in Upcoming Investor Conferences
2022-10-18 20:15 ET
Treace to Report Third Quarter 2022 Financial Results on November 8, 2022
2022-09-27 20:15 ET
Treace Medical Concepts Appoints New Directors
2022-09-13 20:15 ET
Treace Highlights New Product Innovations at the 2022 AOFAS Scientific Conference
2022-09-13 20:05 ET
Treace Announces Updated ALIGN3D™ Data at the 2022 AOFAS Annual Meeting
2022-08-24 20:15 ET
Treace Announces Participation in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-09 20:05 ET
Treace Medical Concepts Reports Second Quarter 2022 Financial Results
2022-08-03 20:15 ET
Treace Announces Full Commercial Release of New Technologies for Bunion and Related Midfoot Surgery
2022-07-25 20:30 ET
Treace to Host Surgeon Advisor Event on September 20, 2022
2022-07-22 12:30 ET
Treace to Report Second Quarter 2022 Financial Results on August 9, 2022
2022-05-05 20:05 ET
Treace Medical Concepts Reports First Quarter 2022 Financial Results
2022-05-05 12:15 ET
Treace Announces Peer-Reviewed Publication of ALIGN3D™ Multicenter Prospective Clinical Data
2022-05-02 12:00 ET
Treace Secures Up to $150 Million in Debt Financing
2022-04-14 20:15 ET
Treace to Report First Quarter 2022 Financial Results on May 5, 2022
2022-03-28 20:15 ET
Treace Files Patent Infringement Suit To Protect Lapiplasty® Bunion Technology
2022-03-03 21:05 ET
Treace Medical Concepts Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-25 17:15 ET
Treace Announces Updated ALIGN3D™ Data at the 2022 ACFAS Scientific Conference
2022-02-23 21:15 ET
Treace Highlights New Product Innovations at the 2022 ACFAS Scientific Conference
2022-02-14 21:15 ET
Treace to Report Fourth Quarter and Full Year 2021 Financial Results on March 3, 2022
2022-02-01 21:15 ET
Treace to Announce Latest ALIGN3D™ Data at the 2022 ACFAS Scientific Conference
2022-01-19 21:15 ET
Treace Announces Grant of U.S. Patent on Instrumented Bunion Correction
2022-01-10 12:00 ET
Treace Medical Concepts Provides 2021 Preliminary Sales Results
2022-01-07 13:00 ET
Treace to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
2021-11-30 21:15 ET
Treace Announces Grant of U.S. Patent and Allowance of U.S. Patent Application on Bone Positioner Technology for Bunion Correction
2021-11-09 21:05 ET
Treace Announces Participation in the Stifel 2021 Virtual Healthcare Conference
2021-11-04 20:05 ET
Treace Medical Concepts Reports Third Quarter 2021 Financial Results
2021-10-21 20:15 ET
Treace Announces Grant of Additional U.S. Patent on Instrumented Bunion Correction
2021-10-14 20:15 ET
Treace to Report Third Quarter 2021 Financial Results on November 4, 2021
2021-10-04 12:00 ET
Treace Medical Concepts Appoints New Directors
2021-10-01 12:00 ET
Treace Announces First Patient Treated in Mini3D™ Lapiplasty® Clinical Study
2021-09-23 20:15 ET
Treace Announces New ALIGN3D™ Data at the 2021 AOFAS Annual Meeting
2021-09-13 20:56 ET
Treace Announces Launch of Adductoplasty™ Instrumented Midfoot Correction System
2021-09-02 20:05 ET
Treace Announces Participation in the Morgan Stanley 19th Annual Global Healthcare Conference
2021-09-01 14:00 ET
Treace Announces New Supportive ALIGN3D™ Data to be Presented at the 2021 AOFAS Annual Meeting
2021-08-05 20:05 ET
Treace Medical Concepts Reports Second Quarter 2021 Financial Results
2021-07-27 20:05 ET
Treace to Report Second Quarter 2021 Financial Results on August 5, 2021
2021-05-25 20:05 ET
Treace Medical Concepts Reports First Quarter 2021 Financial Results
2021-05-19 17:30 ET
Treace Announces Interim Results from ALIGN3D™ Clinical Study at ACFAS 2021
2021-05-18 12:00 ET
Treace to Report First Quarter 2021 Financial Results on May 25, 2021
2021-05-12 12:00 ET
Treace to Announce Interim Results from ALIGN3D™ at ACFAS 2021
2021-04-23 01:00 ET
Treace Medical Concepts Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-02-27 16:29 ET
Treace Medical Concepts, Inc. published news for 2023 q4
SEC form 8
2024-02-27 16:13 ET
Treace Medical Concepts, Inc. published news for 2023 q4
SEC form 8
2024-02-27 16:13 ET
Treace Medical Concepts, Inc. reported for 2023 q4
SEC form 8
2024-02-27 16:13 ET
Treace Medical Concepts, Inc. published news for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Treace Medical Concepts, Inc. published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Treace Medical Concepts, Inc. published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Treace Medical Concepts, Inc. published news for 2023 q4
SEC form 10
2023-11-09 16:14 ET
Treace Medical Concepts, Inc. reported for 2023 q3
SEC form 8
2023-11-09 16:07 ET
Treace Medical Concepts, Inc. reported for 2023 q3
SEC form 10
2023-11-09 00:00 ET
Treace Medical Concepts, Inc. published news for 2023 q3
SEC form 10
2023-08-09 08:09 ET
Treace Medical Concepts, Inc. published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Treace Medical Concepts, Inc. published news for 2023 q2
SEC form 6
2023-08-08 16:08 ET
Treace Medical Concepts, Inc. reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Treace Medical Concepts, Inc. published news for 2023 q2
SEC form 6
2023-06-13 17:09 ET
Treace Medical Concepts, Inc. published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Treace Medical Concepts, Inc. published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Treace Medical Concepts, Inc. published news for 2023 q1
SEC form 6
2023-04-04 07:20 ET
Treace Medical Concepts, Inc. published news for 2023 q1
SEC form 6
2023-03-10 16:13 ET
Treace Medical Concepts, Inc. published news for 2022 q4
SEC form 10
2023-03-08 09:09 ET
Treace Medical Concepts, Inc. reported for 2022 q4
SEC form 10
2023-03-08 00:00 ET
Treace Medical Concepts, Inc. reported for 2022 q4
SEC form 6
2023-03-07 16:07 ET
Treace Medical Concepts, Inc. published news for 2022 q4
SEC form 8
2023-03-07 00:00 ET
Treace Medical Concepts, Inc. reported for 2022 q4
SEC form 6
2023-02-23 16:34 ET
Treace Medical Concepts, Inc. published news for 2022 q4
SEC form 6
2023-02-10 16:01 ET
Treace Medical Concepts, Inc. published news for 2022 q4
SEC form 6
2023-01-09 08:07 ET
Treace Medical Concepts, Inc. published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Treace Medical Concepts, Inc. published news for 2022 q4
SEC form 10
2022-11-09 08:34 ET
Treace Medical Concepts, Inc. reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Treace Medical Concepts, Inc. reported for 2022 q3
SEC form 6
2022-11-08 16:11 ET
Treace Medical Concepts, Inc. published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Treace Medical Concepts, Inc. reported for 2022 q3
SEC form 6
2022-09-27 18:44 ET
Treace Medical Concepts, Inc. published news for 2022 q2
SEC form 10
2022-08-10 09:17 ET
Treace Medical Concepts, Inc. reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Treace Medical Concepts, Inc. reported for 2022 q2
SEC form 6
2022-08-09 16:07 ET
Treace Medical Concepts, Inc. published news for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Treace Medical Concepts, Inc. reported for 2022 q2
SEC form 6
2022-05-23 16:10 ET
Treace Medical Concepts, Inc. published news for 2022 q1
SEC form 10
2022-05-06 09:01 ET
Treace Medical Concepts, Inc. reported for 2022 q1
SEC form 10
2022-05-06 00:00 ET
Treace Medical Concepts, Inc. reported for 2022 q1
SEC form 6
2022-05-05 16:10 ET
Treace Medical Concepts, Inc. published news for 2022 q1
SEC form 8
2022-05-05 00:00 ET
Treace Medical Concepts, Inc. reported for 2022 q1
SEC form 6
2022-05-03 19:11 ET
Treace Medical Concepts, Inc. published news for 2022 q1
SEC form 6
2022-04-04 16:31 ET
Treace Medical Concepts, Inc. published news for 2022 q1
SEC form 6
2022-03-14 18:02 ET
Treace Medical Concepts, Inc. published news for 2021 q4
SEC form 10
2022-03-04 16:06 ET
Treace Medical Concepts, Inc. published news for 2021 q4
SEC form 10
2022-03-04 00:00 ET
Treace Medical Concepts, Inc. published news for 2021 q4
SEC form 6
2022-03-03 16:06 ET
Treace Medical Concepts, Inc. published news for 2021 q4
SEC form 8
2022-03-03 00:00 ET
Treace Medical Concepts, Inc. published news for 2021 q4
SEC form 6
2022-02-25 16:32 ET
Treace Medical Concepts, Inc. published news for 2021 q4
SEC form 6
2022-01-12 16:11 ET
Treace Medical Concepts, Inc. published news for 2021 q4
SEC form 8
2022-01-12 00:00 ET
Treace Medical Concepts, Inc. published news for 2021 q4
SEC form 10
2021-11-04 16:19 ET
Treace Medical Concepts, Inc. published news for 2021 q3
SEC form 6
2021-11-04 16:11 ET
Treace Medical Concepts, Inc. published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
Treace Medical Concepts, Inc. published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Treace Medical Concepts, Inc. published news for 2021 q3
SEC form 6
2021-10-04 21:41 ET
Treace Medical Concepts, Inc. published news for 2021 q3
SEC form 6
2021-10-04 21:40 ET
Treace Medical Concepts, Inc. published news for 2021 q3
SEC form 6
2021-10-04 06:00 ET
Treace Medical Concepts, Inc. published news for 2021 q3
SEC form 6
2021-09-21 16:13 ET
Treace Medical Concepts, Inc. published news for 2021 q2
SEC form 6
2021-08-05 19:18 ET
Treace Medical Concepts, Inc. published news for 2021 q2
SEC form 10
2021-08-05 16:44 ET
Treace Medical Concepts, Inc. published news for 2021 q2
SEC form 6
2021-08-05 16:41 ET
Treace Medical Concepts, Inc. published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Treace Medical Concepts, Inc. published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Treace Medical Concepts, Inc. published news for 2021 q2
SEC form 6
2021-05-28 16:26 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 10
2021-05-25 16:08 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-05-25 16:05 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 10
2021-05-25 00:00 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-27 17:23 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:21 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:17 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:14 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:12 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:12 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:10 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:10 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:07 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:06 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:03 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:03 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:01 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 21:00 ET
Treace Medical Concepts, Inc. published news for 2021 q1
SEC form 6
2021-04-22 20:57 ET
Treace Medical Concepts, Inc. published news for 2021 q1